Pluri, Inc.
(NASDAQ : PSTI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -0.88%725.442.6%$748.08m
AMGNAmgen, Inc. -0.25%230.361.4%$606.98m
BIIBBiogen, Inc. -0.74%260.331.8%$575.78m
MRNAModerna, Inc. -4.13%119.990.0%$565.61m
GILDGilead Sciences, Inc. -0.49%64.631.0%$547.34m
VRTXVertex Pharmaceuticals, Inc. -1.11%295.321.9%$425.16m
ILMNIllumina, Inc. -2.77%206.823.2%$399.44m
SNSSSunesis Pharmaceuticals, Inc. 1.49%4.080.7%$285.21m
SAVACassava Sciences, Inc. -5.60%39.980.0%$179.07m
BNTXBioNTech SE -1.38%135.630.0%$107.89m
TECHBio-Techne Corp. -4.37%295.564.5%$96.36m
BMRNBioMarin Pharmaceutical, Inc. -3.46%88.324.2%$92.61m
PRTAProthena Corp. Plc -2.70%56.9913.8%$77.08m
CRSPCRISPR Therapeutics AG -4.39%62.400.6%$74.79m
NVAXNovavax, Inc. -8.91%16.4775.6%$72.41m

Company Profile

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.